AI-Guided Bronchoscopy Using the Broncho AI Navigator

November 12, 2026 updated by: Ambu A/S

Real-Time AI-Guided Bronchoscopy: A Two-Phase Clinical Study Evaluating Usability and Impact on Procedural Performance Metrics of the Broncho AI Navigator

This clinical investigation evaluates the Ambu Broncho AI Navigator, an investigational software system designed to provide real-time navigational support during bronchoscopy. The system uses artificial intelligence to identify and display airway anatomy during procedures and to help bronchoscopists track which airway segments have been examined.

The study is conducted at Odense University Hospital and consists of two phases. In Phase 2a, experienced bronchoscopists use the system during routine bronchoscopies to evaluate and optimize technical settings and usability. For this phase 45 patients will be enrolled. In Phase 2b, bronchoscopies are randomized (1:1) to be performed with or without the Broncho AI Navigator to evaluate the impact of AI guidance on procedural performance. For this phase 108 patients will be enrolled.

Adult patients undergoing elective bronchoscopy are enrolled, while the primary study subjects are the bronchoscopists performing the procedures. The study evaluates whether use of the Broncho AI Navigator improves bronchoscopy performance by increasing diagnostic completeness, improving structured progression through the bronchial tree, and reducing procedure time. The findings will support further development and future validation of the Broncho AI Navigator in clinical practice.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

153

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Region Syddanmark
      • Odense, Region Syddanmark, Denmark, 5000
        • Recruiting
        • Odense University Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Phase 2a (System calibration):

Inclusion Criteria:

  • Patients indicated for bronchoscopy of central airways as per standard of care.
  • Patients with an age of 18 years or above.

Exclusion Criteria:

  • Patients who are unable to cooperate for bronchoscopy (e.g., patients with mental disorders, cognitive impairment, psychological disorder).
  • Patients who are unable or unwilling to give informed consent.
  • Patients with highly abnormal lung anatomy.
  • Patients with conditions which significantly impact the visual appearance of the airway tissue, such as heavy bleeding, secretions, or inflammation.
  • Patients who are pregnant or breastfeeding
  • Patients previously enrolled in either phase 2a

Phase 2b (Randomized study):

Inclusion Criteria:

  • Patients indicated for bronchoscopy of central airways as per standard of care.
  • Patients with an age of 18 years or above.

Exclusion Criteria:

  • Patients who are unable to cooperate for bronchoscopy (e.g., patients with mental disorders, cognitive impairment, psychological disorder).
  • Patients who are unable or unwilling to give informed consent.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Broncho AI Navigator

The Broncho AI Navigator is an investigational software device designed to provide real-time navigational support during bronchoscopy. The system analyzes live bronchoscopy video using artificial intelligence to identify anatomical landmarks and bronchial segments and displays this information on a monitor to assist navigation through the tracheobronchial tree. The software is evaluated as an adjunct to standard bronchoscopy procedures.

No Intervention: Standard Bronchoscopy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Diagnostic completeness
Time Frame: At the time of the procedure

Diagnostic completeness is defined as the bronchoscopist's ability to visualize all available tertiary bronchial segments (RB1, RB2, RB3, RB4, RB5, RB6, RB7, RB8, RB9, RB10, LB1+2, LB3, LB4, LB5, LB6, LB8, LB9, and LB10) using the bronchoscope. For the purpose of this investigation, a procedure is considered fully diagnostically complete (score of 1) if all tertiary segments are visualized. If any segments are not visualized, the procedure is deemed diagnostically incomplete (score of 0).

At the time of the procedure
Structured progression
Time Frame: At the time of the procedure

The structured progression outcome is scored between 0 and 18, with 18 indicating 18 correct progressions. A point is awarded when the bronchoscopist visualizes one segment and then immediately proceeds to the succeeding segment (e.g., visualizing RB1 followed by RB2 results in a point, whereas RB2 followed by RB1 does not).

At the time of the procedure
Procedure time
Time Frame: At the time of the procedure

Procedure time is defined as the duration required for the bronchoscopist to visualize all 18 segments, starting from the visualization of the first segment to the last.

At the time of the procedure

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 14, 2026

Primary Completion (Estimated)

May 30, 2027

Study Completion (Estimated)

May 30, 2028

Study Registration Dates

First Submitted

November 12, 2026

First Submitted That Met QC Criteria

November 12, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 12, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • CIS-030
  • 16-0300-55 (Other Identifier: Medical Research Ethics Committees (MREC), Denmark)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data (IPD) will not be made publicly available. The study includes clinical procedure data and video recordings collected for medical device development and evaluation. Data contain information that could increase the risk of re-identification, and sharing is restricted to protect participant privacy and confidentiality in accordance with applicable data protection requirements.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.